These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 11271312

  • 1. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
    Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Bismuth H, Groth C.
    Transpl Int; 1994; 7 Suppl 1():S58-63. PubMed ID: 11271312
    [Abstract] [Full Text] [Related]

  • 2. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
    Devlin J, Wong P, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C.
    Transpl Int; 1994; 7 Suppl 1():S64-9. PubMed ID: 11271328
    [Abstract] [Full Text] [Related]

  • 3. Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A.
    McMaster P.
    Transpl Int; 1994; 7 Suppl 1():S32-6. PubMed ID: 11271239
    [Abstract] [Full Text] [Related]

  • 4. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study.
    Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, Otto G, Pichlmayr R, Williams R.
    Transpl Int; 1994 Aug; 7 Suppl 1():S11-4. PubMed ID: 11271178
    [Abstract] [Full Text] [Related]

  • 7. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M, Pellegrini C, Martinelli L, Goggi C, Gavazzi A, Campana C, Arbustini E, Grossi P, Regazzi M, Ippoliti G, Vigano M.
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [Abstract] [Full Text] [Related]

  • 8. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
    Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P.
    Transpl Int; 1994 Oct; 7 Suppl 1():S52-7. PubMed ID: 11271297
    [Abstract] [Full Text] [Related]

  • 9. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 11. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [Abstract] [Full Text] [Related]

  • 12. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients.
    Mueller AR, Platz KP, Schattenfroh N, Bechstein WO, Christe W, Neuhaus P.
    Transpl Int; 1994 Aug; 7 Suppl 1():S37-42. PubMed ID: 11271254
    [Abstract] [Full Text] [Related]

  • 13. Neoral is superior to FK 506 in liver transplantation.
    Levy GA.
    Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
    [No Abstract] [Full Text] [Related]

  • 14. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
    Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW.
    Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
    [Abstract] [Full Text] [Related]

  • 15. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
    Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Bismuth H, Groth C.
    Transpl Int; 1994 Aug; 7 Suppl 1():S27-31. PubMed ID: 11271222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of FK 506 in pancreas transplantation.
    Gruessner RW, Sutherland DE, Drangstveit MB, Troppmann C, Gruessner AC.
    Transpl Int; 1996 Aug; 9 Suppl 1():S251-7. PubMed ID: 8959841
    [Abstract] [Full Text] [Related]

  • 19. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
    Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW.
    Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
    [Abstract] [Full Text] [Related]

  • 20. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation.
    Riva N, Schaiquevich P, Cáceres Guido P, Halac E, Dip M, Imventarza O.
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28574195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.